Current through Register Vol. 48, No. 38, September 20, 2024
a) Any optometrist licensed before January 1,
2008, prior to utilizing or prescribing any oral pharmaceutical agents
permitted under the Act (except non-narcotic oral analgesic and over the
counter agents), shall successfully complete a course of study and testing as
designated in Section
1320.335(b).
Graduates from an approved program of optometry subsequent to January 1, 2008
shall not be required to complete the course and may utilize and prescribe all
oral pharmaceutical agents permitted by the Act.
b) An approved course of study in oral
pharmaceutical agents shall be approved by the Board and shall meet the
following requirements:
1) The program has a
faculty that comprises a sufficient number of instructors to make certain that
the educational obligations to the students are fulfilled. The faculty must
have demonstrated competence in their area of teaching as evidenced by
appropriate degrees from accredited colleges or institutions and clinical and
teaching experience.
2) The program
has a curriculum that contains updates in at least the following areas:
A) Patient medical history/drug
history.
B) General
pharmacokinetics or oral administration.
C) Concerns in special populations.
D) Treatment of ocular disease with oral
pharmaceutical agents, including contraindications, drug interactions, systemic
toxicities and ocular effects for the following:
i) Oral anti-infective agents
* Oral anti-bacterial
* Oral anti-fungals
* Oral anti-virals
ii) Oral anti-glaucoma agents
* CAIs
* Osmotic agents
iii) Oral anti-allergy agents
* Antihistamines
* Mast-cell degranulation inhibitors
* Decongestant combinations
iv) Oral anti-inflammatory agents
* Steroids
* NSAIDS
v) Oral analgesics
* NSAIDS
* Opiates
E) Clinical case studies, including the use
of controlled substances, treatment options, patient management and referral in
the following areas:
i) Infectious ocular
disease
* Bacterial
* Viral
* Fungal
ii) Glaucoma
iii) Allergic eye disease
iv) Inflammatory ocular disease
v) Management of ocular pain
vi) Treatment of drug induced
emergencies
F)
Jurisprudence
Illinois Optometric Practice Act Rules - pharmaceutical
agents
i) Requirements
ii) Restrictions
3) The program includes a minimum
of 12 instructional hours with an examination designed to test the student's
knowledge and ability to apply the program's subject matter.
A) The examination shall be administered and
proctored by a licensed CE sponsor. All examinations must be developed and
approved by a program of optometry approved under Section
1320.20.
B) Verification of student identification
shall be required.
C) The content
of all examinations shall be made available to the Division for review upon
request.
4) In addition
to all other requirements, the program must meet the requirements of Section
1320.80 (Continuing Education).
12 hours of continuing education credit will be granted for successful
completion of the course and test in the renewal period in which the lecture
portion of the course was completed.
5) Requests for course approval must be
submitted to the Division no later than 90 days prior to the beginning of the
course. Sponsors shall provide course documentation and any other documentation
required by the Board.
c)
Failure to successfully complete an approved educational course in oral
pharmaceutical agents prior to March 31, 2010 shall result in the licensee
being placed in non-renewed status until such a course is successfully
completed. A licensee in non-renewed status may not practice optometry within
the State of Illinois.
